Wei-Lun Chang

Title: Innovations of Wei-Lun Chang in Hepatitis B Therapeutic Vaccines

Introduction

Wei-Lun Chang is a notable inventor based in Hsinchu County, Taiwan. He has made significant contributions to the field of medical science, particularly in the development of therapeutic vaccines for hepatitis B. His innovative work has the potential to impact the treatment of this viral infection.

Latest Patents

Wei-Lun Chang holds a patent for a fusion protein designed for use as a hepatitis B therapeutic vaccine. This fusion protein comprises an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a protein transduction domain, and an antigen that includes a hepatitis B virus X protein deletion mutant. The protein transduction domain is a fusion polypeptide that consists of a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is positioned at the N-terminus of the fusion protein, while the antigen is located at the C-terminus of the protein transduction domain. This innovative approach aims to enhance the efficacy of hepatitis B vaccines.

Career Highlights

Wei-Lun Chang is associated with Thevax Genetics Vaccine Co., Ltd., where he continues to advance his research and development efforts. His work in the field of vaccine technology has garnered attention and recognition within the scientific community.

Collaborations

Wei-Lun Chang collaborates with esteemed colleagues, including Chia-Mao Wu and Jiun-Ming Wu. Their combined expertise contributes to the ongoing research and development of innovative solutions in vaccine technology.

Conclusion

Wei-Lun Chang's contributions to hepatitis B therapeutic vaccines exemplify the importance of innovation in medical science. His work not only showcases his inventive spirit but also holds promise for improving public health outcomes.